Multiple Sclerosis – Current Treatment – Current Treatment: Physician Insights – Multiple Sclerosis (EU5)

Numerous disease-modifying therapies (DMTs) have entered the multiple sclerosis (MS) disease landscape in recent years, many of them next-generation alternatives within existing classes. Most recently, TG Therapeutics launched Briumvi, the third-in-class anti-CD20 monoclonal antibody and Sandoz launched Tyruko, the first biosimilar for MS. Given the rapid pace of expansion in the MS market, developers of both current and emerging DMTs must continually reassess their products’ differentiation and positioning in this highly competitive space. This report will explore neurologists’ perceptions of established and recently launched DMTs, their prescribing habits in today’s market, and anticipated changes in brand usage as DMT choices expand—and further complicate—prescribing decisions.

Questions Answered

• How are different MS subpopulations (i.e., clinically isolated syndrome, relapsing-remitting MS, secondary-progressive MS, and primary-progressive MS) treated?
• How do product shares differ across lines of therapy? Which high-efficacy therapies (e.g., Ocrevus) are factoring into early-line treatment decisions?
• What percentage of MS patients have experienced a relapse or disability progression in the past year? What percentage have nonrelapsing SP-MS?
• How have neurologists’ prescribing changed in the past year, and why? What further changes do they expect within the next year?
• What are neurologists’ opinions on the newest entrants in the MS market, and how are they incorporating these DMTs in the treatment paradigm?

Product Description

Through survey data from EU5 physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:

• Understand the treatment landscape for a disease and how physicians make prescribing decisions.
• Evaluate the drivers and obstacles that influence treatment selection.
• Analyze your brand’s performance from the physician perspective to enhance or defend your competitive position.
• Create impactful messaging for physicians by identifying brand differentiators and understanding what motivates prescribing behaviors.

Markets Covered: France, Germany, Italy, Spain, and the United Kingdom.

Primary research: Survey of 50 neurologists in France, Germany, Italy, Spain, and the United Kingdom.

Key drugs covered: Ocrevus, Kesimpta, Briumvi, Tysabri, Tyruko, fingolimod, teriflunomide, Tecfidera, platform injectable therapies

Key companies: Biogen, Novartis, Roche, Sandoz / Polpharma Biologics, TG Therapeutics / Neuraxpharm

Key analyses:

• Factors influencing disease management and treatment decisions.
• Drivers and constraints of treatment selection.
• Physician-reported treatment practices and brand-level patient shares.
• Rationale for changes in treatment approach.
• Physician insight on persistency and compliance.
• Physician-reported recent / anticipated changes in brand usage or treatment approach.